A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Induciā¦ (NCT06603220) | Clinical Trial Compass
CompletedPhase 2
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
United States30 participantsStarted 2024-08-14
Plain-language summary
This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.
Who can participate
Age range18 Years ā 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Confirmed diagnosis of chronic inducible urticaria for at least 3 months.
* Positive response following provocation using the TempTest or FricTest at Screening and Day 1.
Exclusion Criteria:
* History of diseases other than chronic inducible urticaria or chronic spontaneous urticaria with urticaria or angioedema symptoms, such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema.
* Concurrent use of certain medications, including antihistamines.
* Any clinically significant disease, or other skin disease or skin markings (e.g., extensive scarring, tattoos), that might confound the evaluation of safety or efficacy.